Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares. The stock had previously closed at $52.83.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upgraded shares of Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Get Our Latest Report on BPMUF
Basilea Pharmaceutica Stock Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- 3 Warren Buffett Stocks to Buy Now
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- 3 Best Fintech Stocks for a Portfolio Boost
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Best Aerospace Stocks Investing
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
